News
October 20, 2025
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
SHANGHAI and HONG KONG, Oct. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced...
Antengene Corporation, a global biotech firm specializing in innovative cancer treatments, has unveiled promising clinical data for its investigational drug, ATG-022, at the European Society for Medical Oncology (ESMO) Congress 2025. The presentation highlighted the drug's effectiveness in targeting tumors expressing Claudin 18.2 (CLDN18.2), a protein found on the surface of several cancer cells, and showcased its impressive safety profile.
The data, presented earlier today, demonstrated that ATG-022 exhibited significant anti-tumor activity regardless of the level of CLDN18.2 expression in patients. This is a crucial finding because previous CLDN18.2-targeted therapies have often shown limited efficacy in patients with lower levels of the protein. ATG-022's ability to work effectively across all expression levels significantly broadens its potential patient population.
CLDN18.2 is frequently overexpressed in cancers such as gastric, pancreatic, and lung cancers, making it a valuable target for cancer therapies. Antengene's ATG-022 is designed to specifically recognize and bind to this protein, leading to the destruction of cancer cells.
Beyond its efficacy, the clinical trial results also emphasized the exceptional tolerability of ATG-022. Patients treated with the drug experienced minimal side effects, suggesting that it could be a well-tolerated treatment option for individuals battling CLDN18.2-positive tumors. This is particularly important as many existing cancer therapies are associated with debilitating side effects that can negatively impact patients' quality of life.
Antengene, listed on the Hong Kong Stock Exchange (SEHK: 6996.HK), is committed to developing first-in-class and best-in-class medicines for hematologic malignancies and solid tumors. The company believes that ATG-022 has the potential to revolutionize the treatment landscape for CLDN18.2-expressing cancers. The company has expressed optimism about the future development of ATG-022 and its potential to improve the lives of patients with these aggressive cancers. Further clinical trials are planned to further evaluate the drug's efficacy and safety in larger patient populations.
The data, presented earlier today, demonstrated that ATG-022 exhibited significant anti-tumor activity regardless of the level of CLDN18.2 expression in patients. This is a crucial finding because previous CLDN18.2-targeted therapies have often shown limited efficacy in patients with lower levels of the protein. ATG-022's ability to work effectively across all expression levels significantly broadens its potential patient population.
CLDN18.2 is frequently overexpressed in cancers such as gastric, pancreatic, and lung cancers, making it a valuable target for cancer therapies. Antengene's ATG-022 is designed to specifically recognize and bind to this protein, leading to the destruction of cancer cells.
Beyond its efficacy, the clinical trial results also emphasized the exceptional tolerability of ATG-022. Patients treated with the drug experienced minimal side effects, suggesting that it could be a well-tolerated treatment option for individuals battling CLDN18.2-positive tumors. This is particularly important as many existing cancer therapies are associated with debilitating side effects that can negatively impact patients' quality of life.
Antengene, listed on the Hong Kong Stock Exchange (SEHK: 6996.HK), is committed to developing first-in-class and best-in-class medicines for hematologic malignancies and solid tumors. The company believes that ATG-022 has the potential to revolutionize the treatment landscape for CLDN18.2-expressing cancers. The company has expressed optimism about the future development of ATG-022 and its potential to improve the lives of patients with these aggressive cancers. Further clinical trials are planned to further evaluate the drug's efficacy and safety in larger patient populations.
Category:
Technology